Insulet (PODD) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Insulet (NASDAQ:PODD) from a hold rating to a buy rating in a research report sent to investors on Friday, March 9th.

PODD has been the subject of a number of other reports. Zacks Investment Research lowered Insulet from a buy rating to a hold rating in a research report on Saturday, November 11th. Oppenheimer set a $82.00 target price on Insulet and gave the company a hold rating in a research report on Thursday, February 22nd. Barclays reaffirmed a buy rating and set a $78.00 target price on shares of Insulet in a research report on Wednesday, December 13th. UBS raised Insulet from a market perform rating to an outperform rating in a research report on Monday, January 8th. Finally, Raymond James Financial raised Insulet from a market perform rating to an outperform rating and set a $80.00 price target for the company in a research report on Monday, January 8th. Seven analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $73.24.

How to Become a New Pot Stock Millionaire

PODD traded up $0.08 during trading hours on Friday, reaching $85.08. 462,307 shares of the company’s stock traded hands, compared to its average volume of 524,418. Insulet has a 52-week low of $38.43 and a 52-week high of $88.88. The company has a quick ratio of 5.85, a current ratio of 6.24 and a debt-to-equity ratio of 3.57. The stock has a market cap of $5,061.33, a P/E ratio of -184.96 and a beta of 1.37.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The business had revenue of $130.50 million for the quarter, compared to analysts’ expectations of $125.16 million. During the same quarter in the previous year, the firm earned ($0.16) EPS. Insulet’s revenue was up 26.0% compared to the same quarter last year. equities analysts anticipate that Insulet will post -0.29 EPS for the current fiscal year.

In other Insulet news, COO Charles Alpuche sold 7,090 shares of the business’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $84.65, for a total transaction of $600,168.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Shacey Petrovic sold 1,319 shares of the company’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $76.81, for a total value of $101,312.39. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,800 shares of company stock worth $2,412,739. Company insiders own 2.60% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Frontier Capital Management Co. LLC boosted its stake in shares of Insulet by 42.4% in the fourth quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock worth $144,633,000 after buying an additional 624,465 shares during the last quarter. Fred Alger Management Inc. boosted its stake in shares of Insulet by 32.5% in the fourth quarter. Fred Alger Management Inc. now owns 1,808,616 shares of the medical instruments supplier’s stock worth $124,795,000 after buying an additional 443,970 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Insulet by 154.1% in the fourth quarter. Millennium Management LLC now owns 941,567 shares of the medical instruments supplier’s stock worth $64,968,000 after buying an additional 571,082 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Insulet by 328.2% in the fourth quarter. Renaissance Technologies LLC now owns 661,200 shares of the medical instruments supplier’s stock worth $45,623,000 after buying an additional 506,800 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Insulet by 104.9% in the third quarter. JPMorgan Chase & Co. now owns 611,595 shares of the medical instruments supplier’s stock worth $34,035,000 after buying an additional 313,093 shares during the last quarter.

TRADEMARK VIOLATION WARNING: “Insulet (PODD) Stock Rating Upgraded by BidaskClub” was originally published by BBNS and is the property of of BBNS. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://baseballnewssource.com/2018/04/03/insulet-podd-upgraded-to-buy-by-bidaskclub/2017006.html.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.